OP
Background
CFO at Iverline Bio, where I lead finance, IR and corporate development for an early-stage oncology platform out of Cambridge. Previously CFO at Carrick Pharma through its Series A and Series B, with earlier finance leadership roles at Selwyn Biotech and Drumlin Therapeutics. ACA-qualified, and most comfortable buildin…
Experience12 yrsCompanies4
Career History
Jul 2025 – Present1 yrChief Financial Officer at Iverline Bio
Series A11–50 FTEsOncology · Solid tumour
Sitting CFO of a Cambridge oncology biotech, ~32 FTEs post-Series A, now scoping a Series B around lead asset IVR-201 IND clearance.
Apr 2025 – Present1 yr 3 moDirector at Carrick Pharma
Nov 2020 – Mar 20254 yr 4 moChief Financial Officer at Carrick PharmaLondon, England, United Kingdom
Seed → Series A8 → 34 FTEs£22M Series AOncology · Small molecule
Led Carrick's £22M Series A in 2022 from inside the company, scaling the team from 8 to 34 and running HMRC advance assurance and EIS rounds in parallel.
Nov 2017 – Nov 20203 yrFinance Director at Carrick Pharma
Pre-Seed → Seed3 → 8 FTEs£3.5M Seed
Joined as employee #4 and built the finance function from scratch, closing a £3.5M SEIS/EIS seed and standing up R&D tax credit claims.